The Economic Burden of Tenosynovial Giant Cell Tumors Among Employed Workforce in the United States.

Objective: To assess the economic burden of tenosynovial giant cell tumor (TGCT) among US employed workforce.
Methods: Patients with TGCT medical claims (N = 1395) and matched controls (1:10) without TGCT claims (N = 13,950) were identified from the OptumHealth Care Solutions, Inc. database (January 1, 1999 to March 31, 2017). Adjusted regression models were used to compare healthcare resource utilization, time lost from work, and associated costs between cohorts.
Results: In patients with TGCT, the rates of inpatient admissions, emergency room visits, outpatient visits, and work loss days were 2.8, 1.5, 2.2, and 2.6 times those of matched controls, respectively (all P < 0.001). Total annual all-cause healthcare costs and work loss-related costs were $9368 and $2708 higher for TGCT patients than for matched controls, respectively (all P < 0.001).
Conclusions: TGCT was associated with a significant healthcare and work loss burden on US employers.
Competing Interests: Conflicts of Interest: F.L. and W.J.K. are employees of Daiichi Sankyo, Inc. and may own stocks/stock options; F.L. additionally declares owning stocks of Novartis. R.I.I., I.P., W.W., and S.S. are employees of Analysis Group, Inc., which provided paid consulting services to Daiichi Sankyo, Inc. for the conduct of this study. J.A.A. declares receiving research funding from Janssen Oncology, and Novartis.
(Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American College of Occupational and Environmental Medicine.)